reinforced sputnik-v induced spike protein antibody levels in pakistan: an edge of sputnik-v over sinopharm and sinovac as commercially available covid-19 vaccines

Background: despite several challenges, the sars-cov-2 pandemic is still not over. rapid mass-scale immunization is critical to prevent further covid-19-associated deaths.objectives: herein, we aimed to evaluate the rapid ramp-up e ects of spike antibodies in response to sputnik v, sinopharm, and sinovac first dose administration in the general public of pakistan.methods: a cross-sectional study was conducted on 2000 participants to examine sputnik v, sinopharm, and sinovac first dose e ects 21 days post-administration. from 1200 real-time pcr negative subjects, the samples were subjected to sars-cov-2 spike an-tibody levels using electro-chemiluminescence immunoassay (eclia) (elecsys, 09289267190 roche, usa).results: sars-cov-2 spike protein positivity was detected highest at 87% among participants receiving sputnikv with sars-cov-2 spike protein antibodies > 1.5 au/ml compared to 47.6% and 25% in individuals receiving sinopharm and sinovac, respectively. also, 36.04% of the sputnik-administered individuals depicted antibody levels > 250 au/ml. of the participants, 55% had a previous history of covid-19. also, 14.86%, 4.76%, and 0% of the sputnikv, sinopharm, and sinovac administered subjects showed antibodies > 100 au/ml, respectively, while > 25 au/ml antibodies were found in 10.70% of sputnikv, 19.04% of sinopharm and 10.71% of sinovac administered individuals. moreover, > 1.5 - 2.5 au/ml antibodies levels were found in 25.10%, 23.80%, and 14.28% of participants with sputnikv, sinopharm, and sinovac administered vaccines, respectively. the antibody titers of < 1.5 au/ml were detected among 13.30%, 52.38%, and 46.42% of subjects administered with sputnikv, sinopharm, and sinovac vaccines, respectively.conclusions: even before administrating the second booster dose of sputnikv, a significantly higher number of patients depicted rapid ramp-up of sars-cov-2 specific spike antibodies, which can significantly contribute to rapid mass-immunization. despite all challenges, persistent antibody plateau monitoring is critical to attaining humoral immunity against sars-cov-2 infections.